Evidence map›Paper›PMID 38454507›Full record

ArticleBiology direct2024

Dysregulation and antimetastatic function of circLRIG1 modulated by miR-214-3p/LRIG1 axis in bladder carcinoma.

Shiliang Cheng, Chunguang Li, Lu Liu, Xinli Liu, Meng Li, Jinhua Zhuo, Jue Wang, Wen Zheng, Zhongmin Wang

Open access · goldAbstract read
In one paragraph

Article in Biology direct, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Shiliang Cheng *Department of Clinical Laboratory, Shandong Provincial Third Hospital, Cheeloo College of Medicine, Shandong University, Jinan Xingqi Medical Laboratory Co., Ltd., 12 Wuyingshan Middle Road, Jinan, 250000, Shandong, China. chengshiliang2012@126.com.
Chunguang Li *Department of Digestive Oncology, Cancer Hospital of Dalian University of Technology, Liaoning Cancer Hospital and Institute, 44 Xiaoheyan Road, ShenyangLiaoning, 110042, China.
Lu Liu *Department of Digestive Oncology, Cancer Hospital of Dalian University of Technology, Liaoning Cancer Hospital and Institute, 44 Xiaoheyan Road, ShenyangLiaoning, 110042, China.
Xinli LiuDepartment of Clinical Laboratory, Shandong Provincial Third Hospital, Cheeloo College of Medicine, Shandong University, 12 Wuyingshan Middle Road, Jinan, 250000, Shandong, China.
Meng LiDepartment of Clinical Laboratory, Shandong Provincial Third Hospital, Cheeloo College of Medicine, Shandong University, 12 Wuyingshan Middle Road, Jinan, 250000, Shandong, China.
Jinhua ZhuoDepartment of Clinical Laboratory, Shandong Provincial Third Hospital, Cheeloo College of Medicine, Shandong University, 12 Wuyingshan Middle Road, Jinan, 250000, Shandong, China.
Jue WangDepartment of Clinical Laboratory, Shandong Provincial Third Hospital, Cheeloo College of Medicine, Shandong University, 12 Wuyingshan Middle Road, Jinan, 250000, Shandong, China.
Wen ZhengDepartment of Emergency, Shandong Provincial Third Hospital, Cheeloo College of Medicine, Shandong University, 12 Wuyingshan Middle Road, Jinan, 250000, Shandong, China. wenzhengscience@163.com.
Zhongmin WangDepartment of Pharmacy, Shanghai Eastern Hepatobiliary Surgery Hospital, Navy Military Medical University, 225 Changhai Road, Shanghai, 200000, China. 1425842757@qq.com.
Shandong University · CNDalian University of Technology · CNEastern Hepatobiliary Surgery Hospital · CNLiaoning Cancer Hospital & Institute · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

CircLRIG1, a newly discovered circRNA, has yet to have its potential function and biological processes reported. This study explored the role of circLRIG1 in the development and progression of bladder carcinoma and its potential molecular mechanisms. Techniques such as qRT-PCR, Western blot, various cellular assays, and in vivo models were used to investigate mRNA and protein levels, cell behavior, molecular interactions, and tumor growth. The results showed that both circLRIG1 and LRIG1 were significantly reduced in bladder carcinoma tissues and cell lines. Low circLRIG1 expression was associated with poor patient prognosis. Overexpressing circLRIG1 inhibited bladder carcinoma cell growth, migration, and invasion, promoted apoptosis, and decreased tumor growth and metastasis in vivo. Importantly, circLRIG1 was found to sponge miR-214-3p, enhancing LRIG1 expression, and its overexpression also modulated protein levels of E-cadherin, N-cadherin, Vimentin, and LRIG1. Similar effects were observed with LRIG1 overexpression. Notably, a positive correlation was found between circLRIG1 and LRIG1 expression in bladder carcinoma tissues. Additionally, the tumor-suppressing effect of circLRIG1 was reversed by overexpressing miR-214-3p or silencing LRIG1. The study concludes that circLRIG1 suppresses bladder carcinoma progression by enhancing LRIG1 expression via sponging miR-214-3p, providing a potential strategy for early diagnosis and treatment of bladder carcinoma.

Indexed as

CarcinomaMicroRNAsUrinary Bladder NeoplasmsCell Line, TumorCell MovementCell ProliferationGene Expression Regulation, NeoplasticHumansMembrane GlycoproteinsUrinary BladderLRIG1 protein, humanMembrane GlycoproteinsMicroRNAsMIRN214 microRNA, humanBladder carcinomacircLRIG1LRIG1miR-214-3p

Identifiers

PMID38454507
PMCPMC10918934
OpenAlexW4392555036

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.